Amoxicillin & Cephalosporin APIs
$0.30 bnAnnual import
15%Indian capability
6,550Supplier concentration (HHI)
₹2,000 crTo localise
Why India imports it. China controls 80%+ of beta-lactam APIs; India has Aurobindo, Cipla in formulations.
Why it matters. Most-prescribed antibiotic; pandemic shortage exposed risk.
Can India localise it? Yes - 3-5 years for full chain.
Where it comes from. China (80%), India (15%), Italy (5%).
Scorecard
The ten indices
CMDI 75.5Dependency
LPI 57.75Localisation potential
IAI 66.25Investment attractiveness
SRI 73.75Supply risk
SCI 51.5Supply-chain complexity
TRI 40.75Technology readiness
IMI 66.5Industrial multiplier
NSRI 59.75National-security relevance
EPI 65.25Export potential
ICGI 62.25Capability gap
Who makes it
Manufacturers
In India
Aurobindo PharmaCipla LtdHetero Drugs
Global leaders
Huaheng ChemicalNcpcLukang Pharma
On the ground
Localisation projects
- Bulk Drug Park - Nakkapalli (Andhra Pradesh)
Intelligence
Related signals
Sources
Primary references
Confidence: Verified. Verified: PLI for APIs; Aurobindo beneficiary. Part of Techadyant Labs' Critical Manufacturing Dependencies (Edition I).